A risk model developed by researchers can help to identify cancer patients who could benefit from immune checkpoint inhibitors, ICIs. Published in BMC Cancer, the study was conducted at the University ...

Deep learning models had high sensitivity in screening for pulmonary hypertension and congenital heart disease–associated PAH.